Sheikh Mohammed funds AED 8.8m SMA treatment for 16-month-old Jordanian girl

Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, will cover the full treatment cost for 16-month-old Katia Abu Al-Saud, a Jordanian girl with spinal muscular atrophy, at Al Jalila Children's Hospital in Dubai.

The story matters beyond one family because it exposes the operating gap that UAE clinics, insurers and patients face in rare diseases: a single paediatric gene therapy can cost about $2.4 million, or roughly AED 8.8 million at the dirham peg, before travel, diagnostics, monitoring and rehabilitation are counted.

What happened in Dubai

Gulf Daily News reported that the Dubai Ruler would cover Katia's treatment after her family appealed for help. UAE outlets, including The National, reported that Katia has SMA and is expected to receive treatment at Al Jalila Children's Hospital in Dubai.

The treatment cited in regional reports is Zolgensma, a one-time gene therapy used mainly for children under two. Katia was born in April 2025, according to The National, which leaves a narrow treatment window. Her parents first noticed developmental concerns at around six months, then pursued medical tests before the SMA diagnosis.

"We thank Your Highness for this initiative that has restored hope to our daughter," Katia's mother said in a video cited by The Siasat Daily.

The clinical venue is also relevant. Al Jalila Children's Hospital is in Dubai, where healthcare facilities are regulated by the Dubai Health Authority (DHA), while facilities in Abu Dhabi and Al Ain fall under the Department of Health Abu Dhabi (DOH). Providers in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain are under the Ministry of Health and Prevention (MOHAP) or the relevant emirate-level health entities where applicable.

What clinics and insurers should take from it

For Dubai clinics and hospitals, the operational lesson is referral readiness. Rare-disease cases that originate outside the UAE need a defined intake route: medical report review, physician acceptance, pre-arrival estimate, payer confirmation, visa support and a post-treatment follow-up plan. The first commercial question is whether the patient is self-funded, insurer-funded, charity-funded or government-sponsored.

For insurers, the case points to the outer edge of benefit design. Dubai resident policies under DHA rules are built around mandatory coverage, but ultra-high-cost gene therapies need prior authorisation, medical necessity review and clear exclusions or sub-limits. In Abu Dhabi, Daman and the Thiqa programme are central to many resident pathways. In Dubai, private insurers such as Sukoon participate in DHA-linked health insurance products. None of those schemes has been reported as paying for Katia's case.

• AED 8.8 million: approximate reported cost of the gene therapy cited in regional coverage.
• Under two years: the common treatment window reported for Zolgensma use in infant SMA cases.
• 20 August 2026: the date UAE outlets reported the Dubai Media Office announcement.
• Three regulator checks: DHA for Dubai, DOH for Abu Dhabi and Al Ain, MOHAP for the northern emirates.

For CFOs, rare-disease care cannot be priced like routine paediatrics. A provider should separate the drug acquisition cost, administration fee, inpatient monitoring, laboratory work, imaging, rehabilitation and complications reserve. If a number is unavailable, the finance team should request a written pro-forma invoice from the treating hospital and confirm whether the price includes VAT, imported medicine handling, and emergency escalation.

Why patients will ask more questions now

For patients, Katia's case will raise expectations that the UAE can deliver rare-disease care when the right funding is in place. That is useful for Dubai's medical tourism teams, but it creates a communications burden. Clinics should avoid implying that charitable or royal funding is an access pathway. They should publish a named international-patient contact, accepted payment routes, estimated response times and required documents.

Abu Dhabi and the northern emirates will face the same questions. DOH-licensed providers in Abu Dhabi need to explain whether a rare-disease patient can enter through Daman, Thiqa, another private insurer or self-pay. MOHAP-linked providers in the northern emirates need to state whether they treat, refer or stabilise such cases before transfer to Dubai or Abu Dhabi.

The practical next step for operators is simple. Audit rare-disease inquiries from the past 12 months, identify which cases stalled at funding, and update the referral script used by call centres, insurance desks and paediatric specialists. Patients should verify licences, locations and insurance acceptance before booking care through the UAE Open Healthcare Directory, which lists more than 12,384 UAE healthcare providers across all seven emirates.